Syndecan-2 enhances invasive motility in colon cancer cells via a laminin-332–integrin α6β1 axis
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Subin Cho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Ewha Womans University, Seoul, South Korea. Hauptthemen laut MEDLINE: Syndecan-2, Integrin alpha6beta1, Colonic Neoplasms, Cell Adhesion Molecules. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, National Research Foundation of Korea.
Abstract (Originalsprache)
Syndecan-2 (SDC-2) is a key regulator of colon cancer progression, but its cooperation with integrins in cell motility is not fully understood. Here, we show that SDC-2 overexpression in HT29 colon cancer cells (HT29-S2W) enhances adhesion, spreading, and migration on laminin-332, an extracellular matrix component linked to poor prognosis. These effects correlate with increased basal membrane localization of integrin α6, as well as elevated expression and deposition of laminin-332 subunits (α3, β3, and γ2), thereby promoting laminin-332 assembly within the extracellular matrix. Proximity ligation assays revealed enhanced interactions between SDC-2 and integrin α6β1 following SDC-2 overexpression, indicating coordinated signaling mediated by laminin-332. Notably, HT29-S2W cells adhered more efficiently to full-length laminin-332 containing the SDC-2-binding LG4/5 modules of the laminin α3 chain than to truncated laminin-332 lacking these modules. Furthermore, both an anti-integrin α6 antibody and a laminin-α3-derived peptide (A3G75aR) significantly inhibited adhesion to full-length laminin-332. In metastatic DLD-1 cells, which express high levels of SDC-2 and laminin-332, combined treatment with the antibody and peptide markedly suppressed cell migration and invasion. Collectively, these findings identify an SDC-2-laminin-332-integrin α6β1 axis that drives invasive motility and may represent a promising therapeutic target in metastatic colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Ewha Womans University, Seoul, South Korea.
- Laboratory of Cellular Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, Japan.
- Laboratory of Cellular Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Hachioji, Tokyo, Japan. Electronic address: kikkawa@toyaku.ac.jp.
- Department of Life Sciences, Ewha Womans University, Seoul, South Korea. Electronic address: OhES@ewha.ac.kr.
Förderung
- Japan Society for the Promotion of Science
- National Research Foundation of Korea
Zitieren
APA
Cho, S., Hwang, J., Park, E., Yang, H., Matsunuma, M., Hamada, K., Yamada, Y., Kikkawa, Y., & Oh, E. S. (2026). Syndecan-2 enhances invasive motility in colon cancer cells via a laminin-332–integrin α6β1 axis. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113455
Vancouver
Cho S, Hwang J, Park E, Yang H, Matsunuma M, Hamada K, et al. Syndecan-2 enhances invasive motility in colon cancer cells via a laminin-332–integrin α6β1 axis. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113455
BibTeX
@article{Cho2026,
author = {Cho, Subin and Hwang, Jisun and Park, Eunhye and Yang, Hyeonju and Matsunuma, Masumi and Hamada, Keisuke and Yamada, Yuji and Kikkawa, Yamato and Oh, Eok-Soo},
title = {Syndecan-2 enhances invasive motility in colon cancer cells via a laminin-332–integrin α6β1 axis},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113455}
}
EUVIMED